219 related articles for article (PubMed ID: 24027025)
1. Vaccination with leishmania hemoglobin receptor-encoding DNA protects against visceral leishmaniasis.
Guha R; Gupta D; Rastogi R; Vikram R; Krishnamurthy G; Bimal S; Roy S; Mukhopadhyay A
Sci Transl Med; 2013 Sep; 5(202):202ra121. PubMed ID: 24027025
[TBL] [Abstract][Full Text] [Related]
2. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.
Basu R; Bhaumik S; Basu JM; Naskar K; De T; Roy S
J Immunol; 2005 Jun; 174(11):7160-71. PubMed ID: 15905560
[TBL] [Abstract][Full Text] [Related]
3. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
4. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
5. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
Choudhury R; Das P; De T; Chakraborti T
Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
[TBL] [Abstract][Full Text] [Related]
6. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
[TBL] [Abstract][Full Text] [Related]
7. TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis.
Paul J; Karmakar S; De T
Eur J Immunol; 2012 Aug; 42(8):2087-99. PubMed ID: 22622993
[TBL] [Abstract][Full Text] [Related]
8. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
Sharma A; Madhubala R
J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
Stäger S; Smith DF; Kaye PM
J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
[TBL] [Abstract][Full Text] [Related]
11. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
[TBL] [Abstract][Full Text] [Related]
12. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
13. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
Lehmann J; Enssle KH; Lehmann I; Emmendörfer A; Lohmann-Matthes ML
J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
[TBL] [Abstract][Full Text] [Related]
14. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
15. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
Kumari S; Samant M; Misra P; Khare P; Sisodia B; Shasany AK; Dube A
Vaccine; 2008 Oct; 26(45):5700-11. PubMed ID: 18762224
[TBL] [Abstract][Full Text] [Related]
16. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
Bhaumik S; Basu R; Sen S; Naskar K; Roy S
Vaccine; 2009 Feb; 27(9):1306-16. PubMed ID: 19162111
[TBL] [Abstract][Full Text] [Related]
17. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
19. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
